1388 related articles for article (PubMed ID: 25227313)
1. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
Thal DR; Attems J; Ewers M
J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
4. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
Prvulovic D; Hampel H
Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
[TBL] [Abstract][Full Text] [Related]
5. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
6. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.
Maass A; Lockhart SN; Harrison TM; Bell RK; Mellinger T; Swinnerton K; Baker SL; Rabinovici GD; Jagust WJ
J Neurosci; 2018 Jan; 38(3):530-543. PubMed ID: 29192126
[TBL] [Abstract][Full Text] [Related]
7. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
8. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
Attems J; Jellinger KA
Clin Neuropathol; 2006; 25(6):265-71. PubMed ID: 17140156
[TBL] [Abstract][Full Text] [Related]
9. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
12. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.
Merlini M; Wanner D; Nitsch RM
Acta Neuropathol; 2016 May; 131(5):737-52. PubMed ID: 26988843
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
14. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
Pandya S; Kuceyeski A; Raj A;
J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
[TBL] [Abstract][Full Text] [Related]
15. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
17. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
18. Pathology of clinical and preclinical Alzheimer's disease.
Thal DR; von Arnim C; Griffin WS; Yamaguchi H; Mrak RE; Attems J; Upadhaya AR
Eur Arch Psychiatry Clin Neurosci; 2013 Nov; 263 Suppl 2():S137-45. PubMed ID: 24077890
[TBL] [Abstract][Full Text] [Related]
19. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
20. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]